非酒精性脂肪肝潜在药物研究进展

Progress of potential drugs in non-alcohol fatty liver disease

非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是21世纪世界范围的重要的公共健康问题,在中国也越来越得到重视。其发病过程与胰岛素抵抗、肥胖、2型糖尿病及高脂血症密切相关,由于复杂的发病机制,市场上并没有针对NAFLD的特效药。目前,一些相应的治疗药物包括胰岛素增敏剂类、降脂类、抗氧化应激类及保肝类药物等等,也均未能完全逆转NAFLD的发展。治疗NAFLD一线用药的空缺促使研究者进行新颖治疗方法的开发。因此,本文将对各通路的治疗靶点及相关药物的临床研究进行回顾总结,对NAFLD的治疗进行较详细的综述,以期对研究有效改善NAFLD的药物提供一些思路。

Non-alcohol fatty liver disease （NAFLD） is an important public health problem in the 21st century. Increasingly, people are paying attention to NAFLD in China. The onset of NAFLD is closely related to Insulin resistance, Obesity, Type 2 diabetes and Hyperlipoidemia. The pathogenesis of NAFLD is complex and there is no effective medicine to treat it. At present, therapeutic drugs includes insulin sensitizing with improving insulin resistance, lipid-lowering drugs with regulating lipid metabolism, antioxidant drugs against oxidative stress and lipid per-oxidation, and drugs of repairing damaged liver hepatoprotective. But the process is not entirely reversible by these drugs. The vacancy of first-line drugs prompt people to pay more attention to new therapeutic targets. So the article will deal with a detailed review on the potential therapeutic targets and clinical trials of NAFLD. Hope that the study will give some suggestions and guidance to the new drug development of NAFLD.